Patent intelligence · US
US 8080241
Viruses for the treatment of cellular proliferative disorders
Viruses for the treatment of cellular proliferative disorders
Patent details — US 8080241
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 20, 2011
- Expiration
- Dec 15, 2031
- Applicant
- ONCOLYTICS BIOTECH INC.
- Claims
- 48
- CPC classes
- A61K, A61K35/13, A61K35/76, A61K35/761
Quick answer
US 8080241 (Viruses for the treatment of cellular proliferative disorders) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Dec 20, 2011. Expires Dec 15, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ONCOLYTICS BIOTECH INC.
- Grant date
- Expiration
- Claims
- 48
- CPC classes
- A61K, A61K35/13, A61K35/76, A61K35/761, A61K38/13, A61K45/06
More from ONCOLYTICS BIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 11246930
Reoviruses having modified sequences
granted -
US 10596260
Reoviruses having modified sequences
granted -
US 10167452
Viral purification methods
granted -
US 10039827
Reoviruses having modified sequences
granted -
US 9610352
Lyophilized viral formulations
granted -
US 9610309
Liquid viral formulations
granted -
US 9365823
Virus clearance of neoplastic cells from mixed cellular compositions
granted
Frequently asked questions
What is US patent 8080241?
US 8080241 (Viruses for the treatment of cellular proliferative disorders) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Dec 20, 2011. Expires Dec 15, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8080241?
ONCOLYTICS BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 66 pharmaceutical patents for this assignee.
When does US 8080241 expire?
Our index shows an expiration date of Dec 15, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.